Amgen declared the launch of migraine drug Aimovig an unqualified success, but analysts weren’t quite ready to buy into the euphoria. Thanks to that skepticism, the positive third-quarter release met worries about everything from the CGRP drug’s insurance coverage to Medicare changes that could dampen sales of Amgen’s older drugs.
Reageer